The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- DEA Finalizes Rescheduling Hydrocodone Combo Products to Schedule II; Industry Has 45 Days to Prepare Aug. 21, 2014
- FDA Subgroup Data Action Plan: Implications for Future FDA Funding Requests – Maybe For “Off-Label” Promotion Aug. 20, 2014
- DEA Scheduling Still Holding Up Merck’s Suvorexant Despite Head Start; Another Case Study To Support Reform Bills Aug. 19, 2014
See More Research Notes